Targeting microRNAs for immunomodulation.

作者: Lukas T Jeker , Romina Marone

DOI: 10.1016/J.COPH.2015.05.004

关键词:

摘要: microRNAs (miRNA) are small regulatory RNAs exerting pleiotropic functions in virtually any immune cell-type. Dozens of miRNAs with a known function the system constitute interesting drug targets for immunomodulation. Chemical modifications nucleic acid-based miRNA mimics and inhibitors largely solved instability issues but delivery to cells remains major challenge. However, recent success targeting acidic tumor microenvironment is very promising inflammatory diseases. Moreover, molecules being explored as an alternative. Although RNA often considered ‘undruggable’ by progress modulating through encouraging. Computational approaches even allow predictions about specific molecule/RNA interactions. Finally, clinical demonstrates that drugs work humans.

参考文章(54)
Andrea Ventura, Amanda G. Young, Monte M. Winslow, Laura Lintault, Alex Meissner, Stefan J. Erkeland, Jamie Newman, Roderick T. Bronson, Denise Crowley, James R. Stone, Rudolf Jaenisch, Phillip A. Sharp, Tyler Jacks, Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17∼92 Family of miRNA Clusters Cell. ,vol. 132, pp. 875- 886 ,(2008) , 10.1016/J.CELL.2008.02.019
Virginie Olive, Qijing Li, Lin He, mir-17-92: a polycistronic oncomir with pleiotropic functions Immunological Reviews. ,vol. 253, pp. 158- 166 ,(2013) , 10.1111/IMR.12054
Martina Roos, Mario A. E. Rebhan, Matije Lucic, David Pavlicek, Ugo Pradere, Harry Towbin, Gianluca Civenni, Carlo V. Catapano, Jonathan Hall, Short loop-targeting oligoribonucleotides antagonize Lin28 and enable pre-let-7 processing and suppression of cell growth in let-7-deficient cancer cells Nucleic Acids Research. ,vol. 43, ,(2015) , 10.1093/NAR/GKU1090
Robert C. Spitale, Ryan A. Flynn, Qiangfeng Cliff Zhang, Pete Crisalli, Byron Lee, Jong-Wha Jung, Hannes Y. Kuchelmeister, Pedro J. Batista, Eduardo A. Torre, Eric T. Kool, Howard Y. Chang, Structural imprints in vivo decode RNA regulatory mechanisms Nature. ,vol. 519, pp. 486- 490 ,(2015) , 10.1038/NATURE14263
Dirk Haussecker, The Business of RNAi Therapeutics in 2012. Molecular therapy. Nucleic acids. ,vol. 1, ,(2012) , 10.1038/MTNA.2011.9
Jochen Imig, Andreas Brunschweiger, Anneke Brümmer, Boris Guennewig, Nitish Mittal, Shivendra Kishore, Panagiota Tsikrika, André P Gerber, Mihaela Zavolan, Jonathan Hall, miR-CLIP capture of a miRNA targetome uncovers a lincRNA H19–miR-106a interaction Nature Chemical Biology. ,vol. 11, pp. 107- 114 ,(2015) , 10.1038/NCHEMBIO.1713
Isabella Gashaw, Peter Ellinghaus, Anette Sommer, Khusru Asadullah, What makes a good drug target Drug Discovery Today. ,vol. 16, pp. 1037- 1043 ,(2011) , 10.1016/J.DRUDIS.2011.09.007
Dirk Haussecker, The Business of RNAi Therapeutics Human Gene Therapy. ,vol. 19, pp. 451- 462 ,(2008) , 10.1089/HUM.2008.007
Boyana Konforti, More than the Sum of Its Parts Cell Reports. ,vol. 1, pp. 1- 1 ,(2012) , 10.1016/J.CELREP.2012.01.002
Dirk Baumjohann, K. Mark Ansel, MicroRNA-mediated regulation of T helper cell differentiation and plasticity Nature Reviews Immunology. ,vol. 13, pp. 666- 678 ,(2013) , 10.1038/NRI3494